Lauren G. Grau

Transactional Experience: Life Sciences, Healthcare

• Represented DaVita Inc., a leading provider of kidney care services, in its agreement to expand its international operations in Brazil and Colombia and its entry into Chile and Ecuador.
• Represented Hoffmann La-Roche in its acquisition of Carmot Therapeutics Inc., a clinical-stage biotechnology company dedicated to developing therapeutics for people living with metabolic diseases, for an upfront payment of US$2.7 billion and additional milestone payments of up to US$400 million.
• Represented Novant Health, Inc. in its agreement with Tenet Healthcare Corporation (NYSE: THC) to acquire three Tenet hospitals and affiliated operations in South Carolina for approximately US$2.4 billion.
• Represented Myovant Sciences in its exclusive licensing agreement with Accord Healthcare, Ltd., to commercialize relugolix for the treatment of advanced, hormone-sensitive prostate cancer in the European Economic Area, United Kingdom, Switzerland, and Turkey.
• Represented DaVita Inc. in its joint venture with Medtronic to form a new, independent, kidney care-focused medical device company. The new company will focus on developing a broad suite of novel kidney care products and solutions, including future home-based products, to make different dialysis treatments more accessible to patients.
• Represented OMERS Private Equity in its agreement to sell its interest in Forefront Dermatology to global private markets firm Partners Group.
• Represented CA Healthcare Acquisition Corp., a special purpose acquisition company focused on investing in a growth-oriented healthcare company, in its pending business combination with LumiraDx Limited, a next-generation point of care diagnostics testing company. The transaction has an implied pro forma equity value of US$3 billion.
• Represented Steward Health Care System LLC in its sale of five hospitals and related hospital operations in Utah to HCA Healthcare, Inc.
• Represented Steward Health Care System LLC in its acquisition of Tenet Healthcare Corporation’s five hospitals and related hospital operations in Florida’s Miami-Dade and southern Broward counties for approximately US$1.1 billion.
• Represented Atomwise, a leader in using artificial intelligence (AI) for small molecule discovery, in a research collaboration agreement with Bridge Biotherapeutics (KOSDAQ: 288330), a clinical stage biotech company, to launch up to 13 small molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.
• Represented Yuhan Corporation in its joint development and licensing agreement with Boehringer Ingelheim, for the development of dual agonist innovative drugs with the activity of GLP-1 and FGF21 to treat nonalcoholic steatohepatitis (NASH) and related liver disease.
• Represented Yuhan Corporation in its licensing and collaboration agreement with Gilead Sciences, Inc. to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to NASH.
• Represented Yuhan Corporation in its licensing agreement with Janssen, a division of Johnson & Johnson, for the development, manufacturing and commercialization of lazertinib, a non-small cell lung cancer drug candidate.
• Represented Nektar Therapeutics in its in multi-billion dollar global strategic development and commercialization collaboration with Bristol-Myers Squibb Company (NYSE: BMY) for Nektar’s CD122-biased agonist, NKTR-214. Under the terms of the agreement, the companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in more than 20 indications across nine tumor types—including melanoma, renal cell carcinoma, non-small cell lung cancer, bladder and triple negative breast cancer—as well as potential combinations with other anti-cancer agents from either of the respective companies and/or third parties.
• Represented Flatiron Health in its inaugural M&A transaction to acquire Protocol First, a software solutions provider focused on accelerating clinical research.
• Represented Hoffman La-Roche in its acquisition of Ignyta, Inc. (NASDAQ: RXDX), a cancer therapy company, for US$1.7 billion in cash.
• Represented GlaxoSmithKline (GSK) on a novel public-private joint venture and collaboration with the University of North Carolina at Chapel Hill dedicated to seeking a cure for HIV. GSK will invest US$4 million in the partnership each year during the five-year research agreement.
• Represented Genentech, a member of the Roche Group, in its agreement to acquire Seragon Pharmaceuticals, Inc., a biotechnology company focused on selective estrogen receptor degraders to treat hormone receptor-positive breast cancer, for a total amount of up to US$1.7 billion.
• Represented Roche Molecular Systems in its acquisition of Genia Technologies, Inc., a DNA sequencing company, for up to US$350 million, and its acquisition of Bina Technologies Inc., the creator of a big data platform for managing and processing next generation sequencing data.

Transactional Experience: Energy, Information Technology, Telecommunications, Consumer Products, Other

• Represented Texon, L.P., a Houston, Texas-based midstream service provider of butane blending and energy marketing, in its sale to Savage, a global provider of supply chain infrastructure and solutions.
• Represented Enbridge Inc. in an infrastructure development agreement with Divert Inc. to develop projects turning wasted food into renewable natural gas (RNG) across the U.S. for up to more than US$1 billion of capital investments underpinned by long-term, take-or-pay contracts.
• Represented National Western in its US$1.9 billion acquisition by an affiliate of Prosperity Life.
• Represented Fleming Insurance Holdings, a portfolio company of Altamont Capital Partners, in its strategic US$277 million acquisition of JRG Reinsurance Company (JRG Re).
• Represented Darling Ingredients Inc. in its US$1.1 billion acquisition of Valley Proteins.
• Represented Cresta Fund Management and Silverpeak Energy Partners in their agreement with San Joaquin Renewables to invest up to US$165 million to develop and construct a biomass-to-renewable natural gas project near McFarland, California.
• Represented Enbridge, Inc. in its transaction with Encap Flatrock Midstream to acquire Moda Midstream Operating, LLC for US$3 billion in cash.
• Represented American National Group, Inc. as lead transaction counsel in its acquisition by Brookfield Asset Management Reinsurance Partners Ltd. in a transaction valued at US$5.1 billion.
• Represented Bodega Latina Corporation in its acquisition of Smart & Final Holdings, Inc. from funds managed by affiliates of Apollo Global Management, Inc. (NYSE:APO) for approximately US$620 million. Bodega Latina is a subsidiary of Grupo Comercial Chedraui, S.A.B. de C.V.
• Represented AmeriHome Mortgage Company, LLC (AmeriHome) in the sale of AmeriHome by subsidiaries of Athene Holding Ltd. (NYSE:ATH) and funds affiliated with Apollo Global Management to Western Alliance Bancorporation.
• Represented EQT Partners Inc. in connection with the merger of its portfolio company, FocusVision, with Confirmit, a portfolio company of Verdane.
• Represented Safe Harbor Marinas in its sale to Sun Communities, Inc., a publicly traded REIT focused on manufactured housing and recreational vehicle communities, in a transaction for cash and equity valued at US$2.11 billion.
• Represented Eagle Materials Inc. in the sale of its Western Aggregates and Mathews Readymix operations to Teichert, a California-based construction company, for US$93.5 million.
• Represented HMS in the acquisition of Accent, a payment accuracy and cost containment business, from Intrado Corporation for US$155 million.
• Represented TSG Consumer Partners and its portfolio companies in numerous matters, including the US$1.2 billion sale of portfolio company IT Cosmetics, LLC to L’Oreal.
• Represented Siris Capital Group, LLC in its US$654 million acquisition of Xura, Inc. (formerly Comverse).
• Represented KPMG, OMERS Private Equity, Dell, R.R. Donnelley & Sons Company, FLIR Systems, Inc., Thompson Street Capital Partners and a number of private equity funds in M&A and financing transactions.

• State Bar of Texas, Member
• Dallas Bar Association, Member
• DFW Women in IP